Replies to post #16207 on Synaptogenix Inc (SNPX)

[runncoach]

I think if more than 80% of patients show an average improvement over 6 months similar to what we've seen in the first 2 trials in this moderate population we won't have to wait until P3 to reap the rewards. I think that's the biggest knock so far, that is the trial length needs to match up with memantine to really draw the comparison to current SOC. It certainly can't be argued that patients on the drug haven't improved objective test scoring so far.

[XenaLives]

Probably means there is an outside variable that has not been identified. Quite likely genetic or microbiome.

All I can read from this is that the drug is useless in severe patients and slightly better than placebo in moderate patients on average, but the huge standard deviations mean that patients in both cohorts are all over the place.